Market Cap | 69.24M | P/E | - | EPS this Y | 9.40% | Ern Qtrly Grth | - |
Income | -28.13M | Forward P/E | -3.57 | EPS next Y | -6.90% | 50D Avg Chg | 29.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 67.00% |
Dividend | N/A | Price/Book | 1.50 | EPS next 5Y | - | 52W High Chg | -24.00% |
Recommedations | 2.00 | Quick Ratio | 4.25 | Shares Outstanding | 68.27M | 52W Low Chg | 138.00% |
Insider Own | 4.42% | ROA | -37.71% | Shares Float | 65.19M | Beta | 0.71 |
Inst Own | 13.47% | ROE | -69.93% | Shares Shorted/Prior | 275.24K/272.98K | Price | 1.07 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 153,230 | Target Price | 7.52 |
Oper. Margin | - | Earnings Date | May 17 | Volume | 236,640 | Change | -0.93% |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.